To earn CME related to this news article, click here. January 9, 2009 — The US Food and Drug Administration (FDA) has approved fludarabine phosphate tablets for the treatment of B-cell chronic ...
Relugolix and degarelix are both effective in achieving and maintaining sustained castration in advanced prostate cancer. Relugolix’s oral form provides convenience, eliminating the need for frequent ...
CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...
Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...
Today the FDA announced the approval of the gonadotropin-releasing hormone receptor inhibitor degarelix for the treatment of advanced prostate cancer. The injectable drug is the first new drug ...
FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...
Pooled data from five phase III studies of men with prostate cancer (n = 1,925) confirm that androgen deprivation therapy (ADT) with degarelix, a gonadotropin-releasing hormone antagonist, offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results